Extracardiac conduit Fontan surgery was associated with a lower risk of combined thromboembolic events compared to lateral tunnel (HR 0.34; 95% CI 0.13-0.91).
Cohort (n=522)
Blinded adjudication
Yes
Does extracardiac conduit Fontan surgery reduce thromboembolic risk compared to lateral tunnel or atriopulmonary connection in patients with univentricular hearts?
Extracardiac conduit Fontan surgery is associated with a significantly lower risk of thromboembolic events compared to lateral tunnel, independent of atrial arrhythmias and thromboprophylaxis.
Effect estimate: HR 0.34 (95% CI 0.13-0.91)
BACKGROUND Thromboembolic events contribute greatly to morbidity and mortality following Fontan surgery for univentricular hearts. OBJECTIVES This study sought to evaluate the effect of type of Fontan surgery on thromboembolic risk. METHODS A North American multicenter retrospective cohort study enrolled 522 patients with Fontan palliation consisting of an atriopulmonary connection (APC) (21.4%), lateral tunnel (LT) (41.8%), or extracardiac conduit (EC) (36.8%). Thromboembolic complications and new-onset atrial arrhythmia were reviewed and classified by a blinded adjudicating committee. Thromboembolic risk across surgical techniques was assessed by multivariable competing-risk survival regression. RESULTS Over a median follow-up of 11.6 years, 10- and 20-year freedom from Fontan conversion, transplantation, or death was 94.7% and 78.9%, respectively. New-onset atrial arrhythmias occurred in 4.4, 1.2, and 1.0 cases per 100 person-years with APC, LT, and EC, respectively. APC was associated with a 2.82-fold higher risk of developing atrial arrhythmias (p < 0.001), with no difference between LT and EC (p = 0.95). A total of 71 thromboembolic events, 32 systemic and 39 venous, occurred in 12.8% of subjects, for an overall incidence of 1.1%/year. In multivariable analyses, EC was independently associated with a lower risk of systemic (hazard ratio HR: 0.20 vs. LT; 95% confidence interval CI: 0.04 to 0.97) and combined (HR: 0.34 vs. LT; 95% CI: 0.13 to 0.91) thromboembolic events. A lower incidence of combined thromboembolic events was also observed with antiplatelet agents (HR: 0.54; 95% CI: 0.32 to 0.92) but not anticoagulation (p = 0.53). CONCLUSIONS The EC Fontan was independently associated with a lower thromboembolic risk after controlling for time-varying effects of atrial arrhythmias and thromboprophylaxis.
Deshaies等(周四)进行了一项队列研究,涉及需要Fontan姑息治疗的单心室心脏(n=522)。比较了心外导管(EC)Fontan与侧隧道(LT)和心房肺连接(APC)Fontan的联合血栓栓塞事件(HR 0.34,95% CI 0.13-0.91)。心外导管Fontan手术与侧隧道相比,联合血栓栓塞事件的风险较低(HR 0.34;95% CI 0.13-0.91)。
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: